FindTrial
Sign In

Development of FISH panel for Risk Adaptive Approach to Korean multiple myeloma treatment

Characteristics of Korean Multiple Myeloma and Development of FISH panel for Risk Adaptive Approach to Treatment

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0002028
Enrollment
600
Registered
2016-08-26
Start date
2016-02-15
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

National Evidence-based Healthcare Callaborating Agency
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Diagnosed and treated at Seoul National University Hospital for multiple myeloma between 1-Jan-2005 and 31-Dec-2015 2) Korean patients 3) adult patients, defined as those who are 18 years old or older

Exclusion criteria

Exclusion criteria: 1) non-Koreans

Design outcomes

Primary

MeasureTime frame
progression free survival—

Secondary

MeasureTime frame
overall survival ;response to bortezomib;response to thalidomide;progression free survival after hematopoeitic stem cell transplantation (HSCT);response to high dose chemotherapy, conventional—

Countries

Korea, Republic of

Contacts

Public ContactJa Min Byun

Kyung Hee University Hospital

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026